Saturday 17 October 2026 Export LXRX’s income statement to Excel — free account

Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $49.8 million, up 60.2% from fiscal 2024. In the quarter to June 2026, revenue fell 97.6%, EPS fell 800.0%, free cash flow fell 154.1% and total debt fell 8.32%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.

1.52 0.13 −7.88%

Follow LXRX

Alert me

Market cap: $734.2M
P/E: 0.0×
Fwd P/E: −12.1×
Dividend yield: —
F-score: 4/9
Altman Z: −12.11
Beneish M: −1.17
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 2.72

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	5	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 49.96%

Capital & Financial Ratios $m

Market Cap 734.18

Revenue 41.47

Net Income (61.12)

Free Cash Flow (64.99)

Net Debt (139.17)

Current Ratio 13.37

Debt/Equity 0.29

P/E ratio 0.00

Fwd P/E (12.10)

P/S ratio 16.04

P/B ratio 3.81

Past 5Y EPS Growth —

This Y EPS Growth (20.12%)

Next Y EPS Growth (26.11%)

Next Y revenue growth (25.37%)

Next 5Y EPS Growth 6.72%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 53.04%

10-year low 10-year high

P/B against its own 10 years 44.35%

10-year low 10-year high

EV/Sales against its own 10 years 46.33%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	170	238	96	191
Receivables	1	3	2	2
Inventory	0	0	0	1
Other	—	—	—	—
	177	246	102	197

	2023	2024	2025	Q'26
Payables	14	15	3	2
ST’ Debt	—	—	5	—
Other	—	—	—	—
	32	45	21	15

Compound Annual Growth %

	10y	5y	3y
Sales	(9.15%)	15.72%	610.25%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(9.31%)	(7.21%)	(2.81%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	21	1	—	—	—
’25	1	29	14	5	50
’24	1	2	2	27	31
’23	0	0	0	1	1
’22	0	0	0	0	0
’21	0	0	0	0	0
’20	8	9	7	0	24

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(15)	(9)	—	—	—
’25	(44)	17	(24)	(17)	(68)
’24	(55)	(49)	(54)	(21)	(179)
’23	(32)	(38)	(42)	(51)	(162)
’22	(23)	(24)	(19)	(22)	(89)
’21	(25)	(22)	(17)	(23)	(87)
’20	(22)	(46)	(40)	(34)	(143)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(15)	(9)	—	—	—
’25	(44)	17	(24)	(17)	(68)
’24	(55)	(49)	(54)	(22)	(180)
’23	(32)	(38)	(42)	(51)	(162)
’22	(23)	(24)	(19)	(23)	(90)
’21	(25)	(23)	(17)	(23)	(88)
’20	(22)	(46)	(40)	(23)	(132)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.00	(0.07)	—	—	—
’25	(0.07)	0.01	(0.04)	(0.04)	(0.14)
’24	(0.20)	(0.17)	(0.18)	(0.09)	(0.63)
’23	(0.17)	(0.22)	(0.21)	(0.20)	(0.79)
’22	(0.16)	(0.16)	(0.13)	(0.16)	(0.62)
’21	(0.15)	(0.13)	(0.16)	(0.17)	(0.60)
’20	(0.63)	(0.65)	0.71	(0.04)	(0.53)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	7.65	8.07	6.02	1.13	1.03	3.26	1.31	0.92	0.62	0.28	Analyst estimates 2026–2028 Powerpack
	High	19.62	18.00	13.97	8.39	4.47	9.65	3.99	3.79	3.73	1.66
People
People	Employees	168	174	202	184	78	87	135	285	103	81
	Revenue/emp, $m	0.47	0.53	0.31	1.75	0.31	0.00	0.00	0.00	0.30	0.61
Income, $m
Income, $m	Revenue	79	92	63	322	24	0	0	1	31	50
	Gross margin, %	100.00	97.93	96.06	99.00	91.96	100.00	100.00	92.94	98.02	99.45
	EBT	(131)	(136)	(121)	124	(59)	(88)	(102)	(177)	(200)	(50)
	EBT margin, %	(165.85)	(147.95)	(190.71)	38.54	(244.11)	(29,448.99)	(73,341.01)	(14,710.88)	(644.78)	(101.08)
	Net income	(131)	(123)	(121)	130	(59)	(88)	(102)	(177)	(200)	(50)
	Depreciation	3	4	5	5	4	0	1	2	2	2
Per share, $
Per share, $	Revenue	0.76	0.87	0.60	3.03	0.22	0.00	0.00	0.01	0.10	0.14
	Earnings	(1.36)	(1.23)	(1.14)	1.23	(0.53)	(0.60)	(0.62)	(0.79)	(0.63)	(0.14)
	Cash flow	(1.69)	(1.76)	(1.40)	1.07	(1.29)	(0.60)	(0.54)	(0.73)	(0.56)	(0.19)
	Capex	0.00	0.00	0.00	0.00	0.10	(0.01)	(0.01)	0.00	0.00	0.00
	Free cash flow	(1.69)	(1.76)	(1.41)	1.07	(1.19)	(0.61)	(0.54)	(0.73)	(0.56)	(0.19)
	Book value	1.52	0.65	(0.25)	1.10	1.41	0.78	0.71	0.42	0.46	0.30
	Shares, m	104	105	106	106	111	146	166	221	320	363
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	3.40	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	18.61	11.62	11.12	1.37	15.80	1,925.73	2,372.72	292.02	7.62	8.38
	P/B	9.37	15.60	0.00	3.76	2.42	5.05	2.82	3.78	1.62	3.88
	EV/Sales	15.52	10.91	12.46	1.29	9.96	1,642.30	1,736.13	234.53	3.23	7.54
	EV/FCF	(6.99)	(5.39)	(5.30)	3.64	(1.81)	(5.55)	(2.68)	(1.74)	(0.56)	(5.45)
Cash, $m
Cash, $m	Operating cash flow	(176)	(185)	(149)	114	(143)	(87)	(89)	(162)	(179)	(68)
	Capex	0	0	0	0	11	(1)	(1)	0	(1)	—
	Free cash flow	(176)	(186)	(149)	114	(132)	(88)	(90)	(162)	(180)	(68)
Balance, $m
Balance, $m	Working capital	193	217	137	272	111	67	118	145	201	81
	Total debt	101	246	245	245	12	2	50	100	100	54
	Net debt	(245)	(65)	85	(26)	(140)	(84)	(88)	(71)	(138)	(42)
	Shareholders’ equity	157	68	(26)	117	156	114	117	93	146	108
Returns, %
Returns, %	ROA	(23.31)	(26.97)	(33.45)	37.08	(18.85)	(51.52)	(61.56)	(83.60)	(75.93)	(20.83)
	ROIC	0.00	(2,594.22)	(110.26)	97.55	(182.69)	(186.85)	(219.91)	(475.14)	(1,485.93)	(46.81)
	ROE	(59.31)	(109.00)	(575.96)	286.97	(42.84)	(65.01)	(88.37)	(168.50)	(167.66)	(39.72)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
SANA Sana Biotechnology, Inc.	$740.9M	— (loss-making)	—	—	n/m	−5.46% (below 0%: shrinking)	0.00%	0.00%	Compare
IVA Inventiva S.A. Sponsored ADR	$740.0M	— (loss-making)	— (loss-making)	−10.77% (below 0%: shrinking)	n/m	−20,989.22% (below 0%: shrinking)	0.00%	0.00%	Compare
LXRX Lexicon Pharmaceuticals, Inc.	$734.2M	— (loss-making)	— (loss-making)	−97.60% (below 0%: shrinking)	n/m	−154.09% (below 0%: shrinking)	94.36%	(3,835.26%)
IMMX Immix Biopharma, Inc.	$719.6M	— (loss-making)	—	—	n/m	−116.22% (below 0%: shrinking)	—	0.00%	Compare
ACHV Achieve Life Sciences, Inc.	$717.2M	— (loss-making)	—	+54.44% (above 0%: growing)	n/m	−19.01% (below 0%: shrinking)	0.00%	0.00%	Compare
FDMT 4D Molecular Therapeutics, Inc.	$711.0M	— (loss-making)	— (loss-making)	+25,106.67% (above 0%: growing)	n/m	−61.28% (below 0%: shrinking)	100.00%	(2,037.16%)	Compare
ANL Adlai Nortye Ltd. Sponsored ADR	$710.1M	—	—	—	—	+46.03% (above 0%: growing)	—	—	Compare
OABI OmniAb, Inc.	$687.7M	— (loss-making)	— (loss-making)	+244.24% (above 0%: growing)	n/m	+211.16% (above 0%: growing)	95.45%	(49.47%)	Compare
ANNX Annexon, Inc.	$682.5M	— (loss-making)	—	—	n/m	−26.41% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$714.1M	—	—	+149.34%	—	−22.71%	0.00%	0.00%

All 614 Biotechnology stocks →

Lexicon Pharmaceuticals, Inc. (LXRX) key facts

Strength: Lexicon Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $49.8 million, up 60.2% from fiscal 2024.
Lexicon Pharmaceuticals, Inc. (LXRX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, LXRX traded at $1.52, a market capitalization of $734.2 million.
Return on equity was −39.7% and debt-to-equity 0.29.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −12.11 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.